Tags

Type your tag names separated by a space and hit enter

Cardioprotective effects of ω -3 PUFAs in chronic kidney disease.
Biomed Res Int 2013; 2013:712949BR

Abstract

The prevalence rate of chronic kidney disease (CKD) is increasing worldwide, and cardiovascular disease (CVD) is a main cause of death in patients with CKD. The high incidence of CVD in CKD patients is related to chronic inflammation, dyslipidemia, malnutrition, atherosclerosis, and vascular calcification. Omega-3 polyunsaturated fatty acids (ω -3 PUFAs) have been shown to reduce the risk of CVD. In this paper, we review the beneficial effects of ω -3 PUFAs on CVD and the possible cardioprotective mechanisms of ω -3 PUFAs in CKD patients by determining the effect of ω -3 PUFAs in the general population. ω -3 PUFAs have several cardioprotective benefits, such as reducing inflammation, decreasing oxidative stress, inhibiting platelet activity, exerting antiarrhythmic effects, and improving triglyceride levels, in the general population and patients with CKD. Modifications of erythrocyte membrane fatty acid content, including an increased ω -3 index and decreased oleic acid, after ω -3 PUFAs supplementation are important changes related to CVD risk reduction in the general population and patients with CKD. Further basic and clinical studies are essential to confirm the effects of ω -3 PUFAs on vitamin D activation, vascular calcification prevention, cardiovascular events, and mortality in CKD patients.

Authors+Show Affiliations

Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul 110-744, Republic of Korea.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23653897

Citation

Lee, Su Mi, and Won Suk An. "Cardioprotective Effects of Ω -3 PUFAs in Chronic Kidney Disease." BioMed Research International, vol. 2013, 2013, p. 712949.
Lee SM, An WS. Cardioprotective effects of ω -3 PUFAs in chronic kidney disease. Biomed Res Int. 2013;2013:712949.
Lee, S. M., & An, W. S. (2013). Cardioprotective effects of ω -3 PUFAs in chronic kidney disease. BioMed Research International, 2013, p. 712949. doi:10.1155/2013/712949.
Lee SM, An WS. Cardioprotective Effects of Ω -3 PUFAs in Chronic Kidney Disease. Biomed Res Int. 2013;2013:712949. PubMed PMID: 23653897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardioprotective effects of ω -3 PUFAs in chronic kidney disease. AU - Lee,Su Mi, AU - An,Won Suk, Y1 - 2013/04/04/ PY - 2013/01/29/received PY - 2013/03/07/accepted PY - 2013/5/9/entrez PY - 2013/5/9/pubmed PY - 2013/12/16/medline SP - 712949 EP - 712949 JF - BioMed research international JO - Biomed Res Int VL - 2013 N2 - The prevalence rate of chronic kidney disease (CKD) is increasing worldwide, and cardiovascular disease (CVD) is a main cause of death in patients with CKD. The high incidence of CVD in CKD patients is related to chronic inflammation, dyslipidemia, malnutrition, atherosclerosis, and vascular calcification. Omega-3 polyunsaturated fatty acids (ω -3 PUFAs) have been shown to reduce the risk of CVD. In this paper, we review the beneficial effects of ω -3 PUFAs on CVD and the possible cardioprotective mechanisms of ω -3 PUFAs in CKD patients by determining the effect of ω -3 PUFAs in the general population. ω -3 PUFAs have several cardioprotective benefits, such as reducing inflammation, decreasing oxidative stress, inhibiting platelet activity, exerting antiarrhythmic effects, and improving triglyceride levels, in the general population and patients with CKD. Modifications of erythrocyte membrane fatty acid content, including an increased ω -3 index and decreased oleic acid, after ω -3 PUFAs supplementation are important changes related to CVD risk reduction in the general population and patients with CKD. Further basic and clinical studies are essential to confirm the effects of ω -3 PUFAs on vitamin D activation, vascular calcification prevention, cardiovascular events, and mortality in CKD patients. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/23653897/Cardioprotective_effects_of_ω__3_PUFAs_in_chronic_kidney_disease_ L2 - https://dx.doi.org/10.1155/2013/712949 DB - PRIME DP - Unbound Medicine ER -